IBUPROFEN TABLET

Land: Canada

Sprog: engelsk

Kilde: Health Canada

Køb det nu

Hent Produktets egenskaber (SPC)
26-02-2020

Aktiv bestanddel:

IBUPROFEN

Tilgængelig fra:

ANGITA PHARMA INC.

ATC-kode:

M01AE01

INN (International Name):

IBUPROFEN

Dosering:

200MG

Lægemiddelform:

TABLET

Sammensætning:

IBUPROFEN 200MG

Indgivelsesvej:

ORAL

Enheder i pakken:

100

Recept type:

OTC

Terapeutisk område:

OTHER NONSTEROIDAL ANTIIMFLAMMATORY AGENTS

Produkt oversigt:

Active ingredient group (AIG) number: 0108883004; AHFS:

Autorisation status:

APPROVED

Autorisation dato:

2020-04-23

Produktets egenskaber

                                _Page 1 / 40_
PRODUCT MONOGRAPH
IBUPROFEN
Ibuprofen Tablets USP
200mg and 400 mg
Non-Steroidal Anti-inflammatory Drug
Analgesic, Antipyretic Agent
Angita Pharma Inc.
1310 Nobel Street,
Boucherville,
Québec Canada, J4B 5H3
Date of Preparation: February 26, 2020
Control # 236574
_Page 2 / 40_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................... 3
SUMMARY PRODUCT INFORMATION
....................................................................................
3
INDICATIONS AND CLINCAL USE
...........................................................................................
3
CONTRAINDICATIONS
...............................................................................................................
4
WARNINGS AND PRECAUTIONS
..............................................................................................
4
ADVERSE REACTIONS
................................................................................................................
9
DRUG INTERACTIONS
..............................................................................................................
12
DOSAGE AND ADMINISTRATION
..........................................................................................
15
OVERDOSAGE
..................................................................................................................................
16
ACTION AND CLINICAL PHARMACOLOGY
........................................................................
16
STORAGE AND STABILITY
......................................................................................................
17
SPECIAL HANDLING INSTRUCTIONS
..................................................................................
17
DOSAGE FORMS, COMPOSITION AND PACKAGING
......................................................... 18
PART II: SCIENTIFIC INFORMATION
................................................................................
19
PHARMACEUTICAL INFORMATION
..................
                                
                                Læs hele dokumentet
                                
                            

Dokumenter på andre sprog

Produktets egenskaber Produktets egenskaber fransk 26-02-2020

Søg underretninger relateret til dette produkt